LPCN Stock Overview
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.82|
|52 Week High||US$1.89|
|52 Week Low||US$0.71|
|1 Month Change||-7.21%|
|3 Month Change||-55.60%|
|1 Year Change||-45.24%|
|3 Year Change||-57.88%|
|5 Year Change||-79.57%|
|Change since IPO||-95.89%|
Recent News & Updates
|LPCN||US Pharmaceuticals||US Market|
Return vs Industry: LPCN underperformed the US Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: LPCN underperformed the US Market which returned -20.5% over the past year.
|LPCN Average Weekly Movement||10.8%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: LPCN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LPCN's weekly volatility (11%) has been stable over the past year.
About the Company
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company’s primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
Lipocine Fundamentals Summary
|LPCN fundamental statistics|
Is LPCN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LPCN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0085|
|Net Profit Margin||-4.67%|
How did LPCN perform over the long term?See historical performance and comparison
Is LPCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LPCN?
Other financial metrics that can be useful for relative valuation.
|What is LPCN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does LPCN's PS Ratio compare to its peers?
|LPCN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: LPCN is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (540.5x).
Price to Earnings Ratio vs Industry
How does LPCN's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?
Price-To-Sales vs Industry: LPCN is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Pharmaceuticals industry average (4x)
Price to Sales Ratio vs Fair Ratio
What is LPCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||4.5x|
|Fair PS Ratio||9.7x|
Price-To-Sales vs Fair Ratio: LPCN is good value based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (9.7x).
Share Price vs Fair Value
What is the Fair Price of LPCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LPCN ($0.82) is trading below our estimate of fair value ($16.33)
Significantly Below Fair Value: LPCN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LPCN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Lipocine forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LPCN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LPCN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LPCN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LPCN's revenue (46.1% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: LPCN's revenue (46.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LPCN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Lipocine performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LPCN is currently unprofitable.
Growing Profit Margin: LPCN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LPCN is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare LPCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LPCN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: LPCN has a negative Return on Equity (-1.78%), as it is currently unprofitable.
Discover strong past performing companies
How is Lipocine's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LPCN's short term assets ($43.5M) exceed its short term liabilities ($3.5M).
Long Term Liabilities: LPCN's short term assets ($43.5M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: LPCN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LPCN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LPCN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LPCN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Lipocine current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LPCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LPCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LPCN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LPCN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LPCN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mahesh Patel (64 yo)
Dr. Mahesh V. Patel, Ph D., co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997 and serves as its Interim Principal Financial Officer since January 31, 2...
CEO Compensation Analysis
Compensation vs Market: Mahesh's total compensation ($USD1.10M) is above average for companies of similar size in the US market ($USD758.64K).
Compensation vs Earnings: Mahesh's compensation has increased whilst the company is unprofitable.
Experienced Management: LPCN's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: LPCN's board of directors are seasoned and experienced ( 19.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LPCN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lipocine Inc.'s employee growth, exchange listings and data sources
- Name: Lipocine Inc.
- Ticker: LPCN
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$71.454m
- Shares outstanding: 88.50m
- Website: https://www.lipocine.com
Number of Employees
- Lipocine Inc.
- 675 Arapeen Drive
- Suite 202
- Salt Lake City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.